ストックスクリーナーアプリを入手
3.64
2.82%
0.10
前日終値:
$3.54
開ける：
$3.54
24時間の取引高:
50,424
Relative Volume:
0.52
時価総額：
$1.29B
収益：
$842.96M
当期純損益:
$-185.63M
株価収益率:
-6.9215
EPS:
-0.5259
ネットキャッシュフロー:
$-228.52M
1週間 パフォーマンス:
-3.19%
1か月 パフォーマンス:
-2.15%
6か月 パフォーマンス:
-18.02%
1年 パフォーマンス:
+17.80%
1日の値動き範囲:
$3.54
$3.66
1週間の範囲:
$3.4991
$3.74
52週間の値動き範囲:
$2.84
$5.6405
Evotec Se Adr Stock (EVO) Company Profile
EVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.64 | 1.31B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-10-07 | ダウングレード | Jefferies | Buy → Hold |
| 2024-08-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-07-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-04-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-08 | アップグレード | Citigroup | Neutral → Buy |
| 2023-04-04 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-16 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-08-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-01-07 | 再開されました | Citigroup | Neutral |
すべてを表示
Evotec Se Adr (EVO) 最新ニュース
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034 - GlobeNewswire Inc.
Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
SAP Quarterly Statement Q2 202522.07.25News - Ariva
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Stock Information - Evotec
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - BNN Bloomberg
Halozyme Therapeutics stock sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India
Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha
Evotec and Variant Bio partner to develop fibrosis treatments - Investing.com
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders - Center for Biosimilars
Evotec SE ADR earnings, Revenue miss in Q3 By Investing.com - Investing.com India
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Together for Medicines That MatterEvotec - Evotec
Evotec and Biogen Idec in research agreement - Proactive financial news
Evotec Se Adr (EVO) 財務データ
収益
当期純利益
現金流量
EPS
2.37%
0.37%
大文字化:
|
ボリューム (24 時間):